Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin

Ritsuko Nakai; Suguru Fukuhara; Akiko Miyagi Maeshima; Sung-Won Kim; Yuta Ito; Shunsuke Hatta; Tomotaka Suzuki; Sayako Yuda; Shinichi Makita; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Koji Izutsu

doi:10.1002/ccr3.2543

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin

Clin Case Rep. 2019 Nov 15;7(12):2500-2504. doi: 10.1002/ccr3.2543. eCollection 2019 Dec.

Affiliations

¹ Department of Hematology National Cancer Center Hospital Tokyo Japan.
² Department of Pathology National Cancer Center Hospital Tokyo Japan.
³ Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan.

Abstract

This is the first case report of alectinib as a bridge to allo-SCT in a patient with ALK-positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

Keywords: ALK‐positive ALCL; alectinib; hematopoietic stem cell transplantation.

Publication types

Case Reports